BCL2 and non-Hodgkin lymphoma: Despite alternative binding modalities, S55746 binds to G101V mutant BCL2 with 100-fold lower affinity compared to wildtype BCL2.320 Two clinical trials were completed; firstly, to assess the safety and tolerability of S55746 in CLL and NHL (NCT02920697), and secondly, to assess the combination of S55746 and the PI3K inhibitor, idelalisib, in FL and MCL (NCT02603445).